Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 12,739 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 11:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Goodyear, Arizona • Duarte, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Completed No phase listed Observational

Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes

NCT01190904
View directory record Official record
Conditions
Androgen Deficiency, AD, Erectile Dysfunction, ED, Diabetes Mellitus, Coronary Artery Disease, Coronary Revascularization
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Guttenberg, New Jersey • Elmhurst, New York • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 23, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

NCT01646060
View directory record Official record
Conditions
Blood Loss, Healthy
Interventions
CM-1500
Device
Lead sponsor
Zynex Monitoring Solutions
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 4 Interventional Results available

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
Interventions
Zemplar® injection, Hectorol® injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Bellevue, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

NCT01084759
View directory record Official record
Conditions
Prostate Cancer
Interventions
Testosterone injection, Etoposide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Recruiting No phase listed Observational

Ablative Therapy in the Management of Prostate Cancer

NCT03492424
View directory record Official record
Conditions
Prostate Cancer
Interventions
cryotherapy
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2039
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 23, 2026, 11:23 AM EDT
Terminated Phase 3 Interventional

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

NCT00450970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Oral Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
121
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 23, 2026, 11:23 AM EDT
Not yet recruiting Phase 1 Interventional

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

NCT07696962
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)

NCT00923169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Anti-Transforming Growth Factor-beta (GC 1008)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Results available

RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02279641
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NCT03636256
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions
NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Drug · Other
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Not applicable Interventional Results available

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

NCT01585831
View directory record Official record
Conditions
Klinefelter Syndrome, XXY Syndrome
Interventions
Testosterone gel 1%, Placebo gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

NCT03498170
View directory record Official record
Conditions
Interaction
Interventions
BCT197, Itraconazole 200 mg
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 23, 2026, 11:23 AM EDT
Recruiting Phase 4 Interventional

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373
View directory record Official record
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Completed No phase listed Observational

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

NCT06500741
View directory record Official record
Conditions
Prostate Cancer
Interventions
No Intervention
Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 11:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

NCT00870441
View directory record Official record
Conditions
Safety of ASP2151
Interventions
ASP2151, Valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 23, 2026, 11:23 AM EDT
Terminated Phase 1Phase 2 Interventional

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

NCT02805894
View directory record Official record
Conditions
Prostate Cancer
Interventions
NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
Drug
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

NCT00672594
View directory record Official record
Conditions
Prostate Cancer, Prostatectomy
Interventions
Sunitinib Malate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 23, 2026, 11:23 AM EDT
Not yet recruiting Phase 1 Interventional

Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

NCT03653702
View directory record Official record
Conditions
Vesico-Ureteral Reflux
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 35 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 23, 2026, 11:23 AM EDT